HUP9802664A2 - Módosított Meningococcus poliszaharidot tartalmazó konjugált vakcina és módosított poliszacharidok - Google Patents

Módosított Meningococcus poliszaharidot tartalmazó konjugált vakcina és módosított poliszacharidok

Info

Publication number
HUP9802664A2
HUP9802664A2 HU9802664A HUP9802664A HUP9802664A2 HU P9802664 A2 HUP9802664 A2 HU P9802664A2 HU 9802664 A HU9802664 A HU 9802664A HU P9802664 A HUP9802664 A HU P9802664A HU P9802664 A2 HUP9802664 A2 HU P9802664A2
Authority
HU
Hungary
Prior art keywords
stone
polysaccharide
modified
subject
fragment
Prior art date
Application number
HU9802664A
Other languages
English (en)
Inventor
Harold J. Jennings
Michele Lussier
Francis Michon
Robert Pon
Original Assignee
National Research Council Of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council Of Canada filed Critical National Research Council Of Canada
Publication of HUP9802664A2 publication Critical patent/HUP9802664A2/hu
Publication of HUP9802664A3 publication Critical patent/HUP9802664A3/hu
Publication of HU224972B1 publication Critical patent/HU224972B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány tárgyát kémiailag módősítőtt, B csőpőrthőz tartőzómeningőcőccűs pőliszacharid képezi, amelyben az N-acetil-csőpőrtőkatvalamely (I) általánős képletű N-acilcsőpőrt helyettesíti, ahől a kép-letben R1 jelentése 3-4 szénatőmős telítetlen alkilcsőpőrt, amely legalábbegy kettőskötést tartalmaz. A találmány tárgyáhőz tartőznak őlyan kőnjűgált mőlekűlák is, amelyeklegalább egy (IIa) általánős képletű pőliszacharid fragmentű-mőttartalmaznak, ahől a képletben R2 jelentése telítetlen acilcsőpőrt,amelyek legalább egy kettőskötést tartalmaz, és ahől a fragmentűmkővalens kötéssel egy fehérjéhez van kötve. A találmány tárgyát képezi tővábbá őlyan vakcinakészítmény, amely afenti kőnjűgált mőlekűlát tartalmazza, amelyben pőliszacharidfragmentűmként B csőpőrthőz tartőzó meningőcőccűs pőliszacharid 3-5szénatőmős telítetlen N-acil-származéka, valamint egy fehérjekőmpőnens van jelen. A fehérje kőmpőnens előnyösen Neisseriameningitidisből származik. A találmány szerinti vakcina eredményesen alkalmazható menin-gitidiselleni imműnizálásra. ŕ
HU9802664A 1995-06-07 1996-06-07 Modified meningococcal polysaccharide conjugate vaccines and modified polysaccharides HU224972B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/484,569 US5811102A (en) 1995-06-07 1995-06-07 Modified meningococcal polysaccharide conjugate vaccines
PCT/CA1996/000379 WO1996040239A1 (en) 1995-06-07 1996-06-07 Modified meningococcal polysaccharide conjugate vaccines

Publications (3)

Publication Number Publication Date
HUP9802664A2 true HUP9802664A2 (hu) 1999-02-01
HUP9802664A3 HUP9802664A3 (en) 1999-12-28
HU224972B1 HU224972B1 (en) 2006-04-28

Family

ID=23924694

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802664A HU224972B1 (en) 1995-06-07 1996-06-07 Modified meningococcal polysaccharide conjugate vaccines and modified polysaccharides

Country Status (18)

Country Link
US (4) US5811102A (hu)
EP (1) EP0831898B1 (hu)
JP (2) JP4171068B2 (hu)
KR (1) KR100452475B1 (hu)
CN (1) CN1163270C (hu)
AT (1) ATE238064T1 (hu)
AU (1) AU706053B2 (hu)
BR (1) BR9609229A (hu)
CA (1) CA2223567C (hu)
CZ (1) CZ391497A3 (hu)
DE (1) DE69627652T2 (hu)
ES (1) ES2196153T3 (hu)
HU (1) HU224972B1 (hu)
IL (3) IL147121A (hu)
NO (1) NO321705B1 (hu)
PL (1) PL184125B1 (hu)
WO (1) WO1996040239A1 (hu)
ZA (1) ZA964823B (hu)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US6048527A (en) 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions
DK0939647T4 (da) * 1996-08-27 2006-10-23 Novartis Vaccines & Diagnostic Neisseria Meningitidis-serogruppe B-glycokonjugat og fremgangsmåde til anvendelse deraf
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
KR100757630B1 (ko) * 1997-12-23 2007-09-10 박스터 헬쓰케어 에스.에이. 신규한 추출 및 단리 방법으로 수득되는 세균성 캡슐형 다당류
NZ509986A (en) * 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US6585973B1 (en) * 1998-10-29 2003-07-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method for preparing solid phase conjugated vaccine
CA2279134A1 (en) * 1999-07-29 2001-01-29 Tianmin Liu Novel strategy for carbohydrate-based therapeutic vaccines
AU2001278323A1 (en) * 2000-07-28 2002-02-13 National Research Council Of Canada Modified sialic acid vaccines
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
AP1897A (en) 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
RU2322451C2 (ru) * 2001-04-17 2008-04-20 Новартис Вэксинс Энд Диагностикс, Инк. Молекулярные миметики эпитопов менингококка в, которые вызывают выработку функционально активных антител
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
CN102302776B (zh) * 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 抗多种脑膜炎球菌血清组的可注射性疫苗
AU2004251734B2 (en) * 2003-06-23 2010-11-04 Baxalta GmbH Vaccines against group Y neisseria meningitidis and meningococcal combinations thereof
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
MXPA06015107A (es) * 2004-06-23 2007-03-26 Childrens Hosp & Res Ct Oak Derivados de polisacaridos y sus usos en la induccion de una respuesta inmune.
WO2006096970A1 (en) * 2005-03-14 2006-09-21 Governors Of The University Of Alberta Synthetic anti-candida albicans oligosaccharide based vaccines
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
ES2383209T3 (es) 2006-03-22 2012-06-19 Novartis Ag Regímenes para la inmunización con conjugados meningococicos
US10828361B2 (en) * 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
GB0611914D0 (en) * 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
ATE511398T1 (de) 2006-09-07 2011-06-15 Glaxosmithkline Biolog Sa Inaktiviertes poliovirus mischimpfstoff
ES2621359T3 (es) * 2007-06-20 2017-07-03 Pfizer Ireland Pharmaceuticals Polisacáridos modificados para vacunas conjugadas
WO2010064437A1 (ja) 2008-12-03 2010-06-10 株式会社カネカ ホルミル基含有多孔質担体、それを用いた吸着体、およびそれらの製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) * 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4619828A (en) * 1982-07-06 1986-10-28 Connaught Laboratories, Inc. Polysaccharide exotoxoid conjugate vaccines
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US4496538A (en) * 1982-07-06 1985-01-29 Connaught Laboratories, Inc. Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine
NZ214503A (en) * 1984-12-20 1990-02-26 Merck & Co Inc Covalently-modified neutral bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins, and methods of preparing such polysaccharides and conjugates
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5034516A (en) * 1987-08-04 1991-07-23 University Of Ottawa Synthetic antigens of sialic acid and derivatives thereof
WO1990006696A2 (en) 1988-12-19 1990-06-28 Praxis Biologics, Inc. Meningococcal class 1 outer-membrane protein vaccine
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
FI903414A (fi) 1990-07-06 1992-01-07 Kansanterveyslaitos Produktion av proteiner i grampositiva bakterier.
FR2682388B1 (fr) * 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
US5780606A (en) * 1995-06-07 1998-07-14 Connaught Laboratories Limited Neisseria meningitidis capsular polysaccharide conjugates
US6048527A (en) * 1996-08-27 2000-04-11 Chiron Corporation Antibodies that define unique Meningococcal B epitopes and vaccine compositions

Also Published As

Publication number Publication date
US20020031511A1 (en) 2002-03-14
CN1187136A (zh) 1998-07-08
ZA964823B (en) 1997-08-01
US6596283B2 (en) 2003-07-22
NO975547D0 (no) 1997-12-02
WO1996040239A1 (en) 1996-12-19
IL118604A0 (en) 1996-10-16
JP2008285675A (ja) 2008-11-27
HUP9802664A3 (en) 1999-12-28
US5811102A (en) 1998-09-22
ATE238064T1 (de) 2003-05-15
PL184125B1 (pl) 2002-09-30
US6350449B1 (en) 2002-02-26
US5969130A (en) 1999-10-19
CA2223567C (en) 2009-02-03
DE69627652T2 (de) 2004-02-12
AU706053B2 (en) 1999-06-10
CZ391497A3 (cs) 1998-05-13
KR100452475B1 (ko) 2004-12-30
EP0831898B1 (en) 2003-04-23
EP0831898A1 (en) 1998-04-01
PL323862A1 (en) 1998-04-27
IL147121A0 (en) 2002-08-14
NO975547L (no) 1998-02-09
DE69627652D1 (de) 2003-05-28
JP4171068B2 (ja) 2008-10-22
AU5993796A (en) 1996-12-30
ES2196153T3 (es) 2003-12-16
JPH11506491A (ja) 1999-06-08
CA2223567A1 (en) 1996-12-19
HU224972B1 (en) 2006-04-28
CN1163270C (zh) 2004-08-25
IL147121A (en) 2009-07-20
BR9609229A (pt) 1999-07-27
KR19990022748A (ko) 1999-03-25
NO321705B1 (no) 2006-06-26

Similar Documents

Publication Publication Date Title
HUP9802664A2 (hu) Módosított Meningococcus poliszaharidot tartalmazó konjugált vakcina és módosított poliszacharidok
HUP0001319A2 (hu) Heteroaril-hexanolsav-amid származékok, azok előállítása és szelektív inhibitorokként történő alkalmazása az MIP-1alfa saját CCR1 receptoraihoz való kapcsolódásának megakadályozására
LU91924I2 (fr) Composition vaccinale comprenant le polysaccharidecapsulaire et Haemophilus influenzae type b coupl é à l'anatoxine tétanique, l'antigène diphtérique,l'antigène tétanique, des antigènes de la polio, des antigènes de la coqueluche et du phosphate d'aluminium
HUP9900061A1 (hu) Alumínium-foszfátra adszorbeált konjugált poliszacharid antigént tartalmazó vakcinakompozíciók
EA200501070A1 (ru) Поливалентная вакцинная композиция
HUP0303376A2 (hu) Acilezett piperidinszármazékok mint melanokortin-4 receptor agonisták, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0002475A2 (hu) Módosított immunogén pneumolizinkészítmények mint vakcinák
DE60230670D1 (de) Staphylococcus aureus exopolysaccharid und verfahren
BR0206672A (pt) Vacina conjugada de proteìna de polissacarìdeo meningocócico multivalente
WO2006002402A3 (en) Polysaccharide derivatives and uses in induction of an immune response
BR0009163A (pt) Vacina
DE3484691D1 (de) Konjugierte vinblastin-verbindungen und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IS3753A7 (is) Endurbætt aðferð og samsetning bóluefnis
BRPI0410341A (pt) conjugados de polissacarìdeo-proteìna derivatizados de meningococos multivalente e vacina
FR2610631B1 (fr) Molecules comportant au moins une sequence peptidique porteuse d'un ou plusieurs, epitope caracteristique d'une proteine produite par p. falciparum dans les hepatocytes, et leurs utilisations, notamment pour le diagnostic du paludisme ou dans des compositions de vaccins contre le paludisme
KR900701807A (ko) 갈라비오 사이드 아날로그, 이를 포함한 약학적 조성물 및 그용도
HUP9901212A2 (hu) N,N-dialkil-N-[2-(3-alkoxi-fenoxi)-etil]-amin-származékok, az ezeket tartalmazó gyógyszerkészítmények és helyi érzéstelenítőkként való alkalmazásuk
DE60041067D1 (de) Verfahren zur herstellung hochreiner nicht toxischer toxinfragmente
ATE254137T1 (de) ßLIGAND PRESENTING ASSEMBLYß (LPA), VERFAHREN ZU DESSEN HERSTELLUNG UND VERWENDUNGEN
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
BR0313019A (pt) Compostos que se ligam a p-selectina
BG103271A (en) Derivatives of n-(benzothiazol-2-yl) piperidine-1-ethaneamines, method for their preparation and application as therapeutical means
YU41796A (sh) Smeše za poboljšanje podnošljivosti delotvornih beta-amino kiselina
HUP9702293A2 (hu) 4-Tiazolidinon-, rodanin- és 1,3-oxatiolán-5-on-származékok alkalmazása sclerosis multiplex kezelésére alkalmas gyógyszerkészítmények előállítására
ATE393160T1 (de) Derivative von 9,10-dihydro-9-oxa-10- phosphaphenanthren-10-oxid

Legal Events

Date Code Title Description
MM4A Lapse of definitive patent protection due to non-payment of fees